ANDA 210558, held by Somerset Theraps LLC. Isosulfan Blue.
As of Nov 16, 2026, ANDA 210558 (Isosulfan Blue), held by Somerset Theraps LLC, was first approved by FDA on Jul 12, 2019, with 0 approved supplements and 0 published complete response letters.
Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities. 1.1 Lymphatic Vessel Delineation Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 12, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Isosulfan Blue50MG/5ML (10MG/ML) · solution;subcutaneous | Isosulfan Blue | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters